GlassScriptPhysician profile
Bruce C Friedman
NPI 1417939315
$629,289.11
in general payments reported to CMS, 2019-2025
33 companies · $32K in 2025
The $32K reported for 2025 was more than what 98% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221K · 2020: $46K · 2021: $88K · 2022: $126K · 2023: $95K · 2024: $21K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $85K · Travel and Lodging: $20K · Consulting Fee: $18K · Honoraria: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,900 · Food and Beverage: $3,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $84,860.00 |
| Travel and Lodging | $20,015.98 |
| Consulting Fee | $18,009.00 |
| Honoraria | $11,799.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,900.00 |
| Food and Beverage | $3,190.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $172,168.15 | 2019-2025 | Fetroja |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115,094.98 | 2019-2023 | Relistor, Xifaxan |
| Acelrx Pharmaceuticals, INC. | $60,475.75 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $58,252.69 | 2019-2023 | Xerava, Giapreza |
| Portola Pharmaceuticals, LLC | $53,911.79 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $46,678.44 | 2019-2022 | |
| Melinta Therapeutics, LLC | $28,045.72 | 2019-2023 | Vabomere |
| Merck Sharp & Dohme LLC | $22,082.85 | 2019-2023 | |
| Astellas Pharma US INC | $16,225.78 | 2019-2022 | |
| Medline Industries LP | $13,949.34 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $11,215.02 | 2019 | |
| Btg International INC. | $7,683.14 | 2025 | Aurlumyn |
| Allergan, INC. | $5,491.56 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $5,430.79 | 2022-2023 | Andexxa |
| Alexion Pharmaceuticals, INC. | $3,450.00 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,750.00 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $2,509.88 | 2019 | |
| Baudax Bio INC. | $1,105.00 | 2021 | |
| Cipla USA INC. | $679.90 | 2021-2025 | |
| Kerecis Limited | $476.64 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Bard Peripheral Vascular, INC. | $300.00 | 2019 | |
| Bard Access Systems, INC. | $300.00 | 2020 | |
| Bioventus LLC | $186.62 | 2023 | Sonicone Clinic |
| Cook Medical LLC | $182.24 | 2019-2020 | |
| Avita Medical Americas, LLC | $157.25 | 2020 | |
| Ambu INC. | $129.64 | 2025 | |
| Trevena, INC. | $79.63 | 2021 | |
| Ovik Health, LLC | $67.00 | 2019 | |
| Sientra, INC. | $65.38 | 2019 | |
| Smith+Nephew, INC. | $58.08 | 2022 | |
| Potrero Medical, INC. | $39.75 | 2022 | |
| Janssen Biotech, INC. | $25.54 | 2025 | Tremfya |
| Bioxcel Therapeutics, INC. | $20.56 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.